

FRESH THINKING AND THE NEWEST ADVANCES START HERE

PROGRAM HIGHLIGHTS

This seminar series focuses on key challenges of the prevention, treatment and patient management approaches associated with viral hepatitis, advancing cirrhosis, liver cancer and fatty liver disease.

- ▶ Updated content based on the latest medical guidelines and clinical trial results
- ▶ Strong patient-focused educational sessions employing evidence-based studies from the latest AASLD, EASL and DDW programs
- ▶ Local experts at each program provide an interdisciplinary, team approach to patient care
- ▶ A highly interactive format that stresses improved patient outcomes
- ▶ BONUS SESSION on SARS-CoV-2 and Liver Disease
- ▶ Participants can receive up to **10.0 AMA PRA Category 1 Credits™** or up to **12 nursing education** credits

WHO SHOULD ATTEND?

This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

THE BENEFITS OF PARTICIPATION

- ▶ Acquire countless practice ‘pearls’ from the nation’s top liver disease specialists
- ▶ Gain new insight on the cutting edge approaches to optimize clinical outcomes for your patients
- ▶ Participate with local colleagues to solve real-world clinical cases
- ▶ Utilize the clinical resources and referral opportunities found in your community
- ▶ Increase your competence and confidence to better manage patients with hepatitis and other diseases of the liver



This seminar is also available in a MoC approved online, enduring material.

See <http://bit.ly/hepandCLD21> for more details.



SEPTEMBER 10-11

Kansas City, MO

Marriott Country Club Plaza

Bradley Freilich, MD
Kansas City Research Institute

Ryan Taylor, MD
University of Kansas Medical Center

Nancy Todd, APRN
University of Kansas Medical Center



SEPTEMBER 17-18

Phoenix, AZ

Desert Willow Conference Center

Richard A. Manch, MD
Arizona Liver Health

Hugo Vargas, MD, MS
Mayo Clinic

Ann Moore, FNP-C
Arizona Liver Health



SEPTEMBER 24-25

Cincinnati, OH

The Graduate Cincinnati

Kenneth Sherman, MD, PhD
University of Cincinnati

Naga Chalasani, MD
Indiana University

Carrie Jennings, CNP
UC Health Medical Center



OCTOBER 1-2

Durham, NC

Sheraton Imperial Hotel

Sidney Barritt, IV, MD, MSCR
University of North Carolina

Andrew Muir, MD
Duke University

Elizabeth Goacher, PA-C
Duke University Hospital



OCTOBER 15-16

Denver, CO

The Curtis Hotel

Lisa Forman, MD
University of Colorado Health

Avash Karla, MD
Presbyterian/St Luke's Medical Center

Amy Brumenschenkel, AGNP-C
University of Colorado Health



OCTOBER 29-30

Dallas, TX

Embassy Suites Dallas Park Central

Jacqueline O'Leary, MD, MPH
Dallas VA Medical Center

Amit Singal, MD
UT Southwestern Medical Center

Arjmand Mufti, MD
UT Southwestern Medical Center

Jordan Mayberry, PA-C
UT Southwestern Medical Center

Non-Profit Org.
U.S. Postage
Paid
Louisville, Ky.
Permit No. 769


UNIVERSITY OF
LOUISVILLE
Continuing Medical Education &
Professional Development
University of Louisville
Louisville, KY 40292

PREVENTION & THERAPIES FOR
HEPATITIS AND
CHRONIC LIVER
DISEASE



Available as a live, in-person seminar and a MoC approved web-based enduring material.

PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE



An evidence-based seminar focused on
Viral Hepatitis, ESLD, HCC, PBC and NASH

COVID-19 Precautions at Our Seminars

The health and safety of our course participants is paramount and, as recommended by local health authorities, we will implement a host of CDC recommendations including:

- ▶ All public spaces and equipment will be thoroughly disinfected before and during the sessions.
- ▶ Seating will include appropriate distancing and we will limit the total number of participants - inclusive of faculty, staff and exhibitors.
- ▶ Hand sanitizing stations and protective masks will be made available.
- ▶ Hotel banquet staff will wear protective gloves and face masks.
- ▶ Food and beverage areas will be cleaned and disinfected regularly throughout the session.
- ▶ Appropriate packaging and protective barriers at food and beverage stations.

ENHANCE YOUR Knowledge | Competence | Confidence

SEMINAR OVERVIEW

This seminar series will provide updates on the diagnosis and treatment of the dominant forms of viral hepatitis and explore the latest data on advancing liver disease, hepatocellular carcinoma, fatty liver disease and other hepatic conditions.

Location-specific faculty experts will deliver state-of-the-art material utilizing a curriculum that features lectures, case analysis, current clinical trial outcomes and progress reports on promising prevention approaches and emerging therapies.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment, and care management approaches in a setting that stresses interactive learning, audience participation, and collaborative discussion.

Available in two formats, the program will increase the number of clinicians educated in preventing, diagnosing, treating, and/or referring liver-disease patients for more advanced care. The goal of this CME activity is to limit future cases and improve the outcomes of those already infected.

NEW FOR 2021:

- ▶ We have combined the content of two outstanding seminars into **one, comprehensive seminar** focused on preventing and treating the most challenging liver diseases.
- ▶ New and Updated clinical cases to test your knowledge of both **clinical theory and actual practice**.
- ▶ In the shadow of the COVID-19 pandemic, the newest module, **SARS-CoV-2 and Liver Disease** presents the effects of COVID on the liver and patients with advanced liver disease.
- ▶ Increased program flexibility allows you to participate in a **live, F-2-F seminar, or a web-based activity** or an **MoC approved, web-based activity** - each eligible to Category I CME credits™.

WHY YOU SHOULD PARTICIPATE

- ▶ **UPDATE** your clinical knowledge with expert faculty and internationally recognized studies
- ▶ **VALIDATE** your clinical decision processes and patient care approaches
- ▶ **COLLABORATE** with local colleagues to discuss new diagnostic and treatment options

PROGRAM AGENDA

DAY 1	
1:00 - 6:30pm	<ul style="list-style-type: none"> ▶ <i>Introduction, Overview and Pre-test</i> ▶ Viral Hepatitis: The discovery of HCV and its natural history ▶ Update on HCV Diagnosis and Treatment ▶ The Epidemiology of Hepatitis B and Anti-viral therapies ▶ The growing relationship between HBV and HDV ▶ An EASL Briefing on Hepatitis B, C and Delta ▶ Clinical cases analysis ▶ <i>Reception and Networking with industry leaders</i>
DAY 2	
8:00am - 3:30pm	<ul style="list-style-type: none"> ▶ End-stage liver disease and managing the complications of cirrhosis ▶ The liver transplant process and challenges ▶ Hepatocellular Carcinoma: Diagnosis, Management Options and new immunotherapies ▶ The resurgence of Hep A and Alcoholic Liver Disease ▶ <i>Luncheon presentation and View exhibits</i> ▶ SARS-CoV-2 and the Liver ▶ The epidemiology, demographics and diagnosis of NAFLD and NASH ▶ Current and emerging therapies for NASH ▶ Lifestyle changes as a therapeutic agent for fatty liver ▶ PSC and PBC – Clinical Briefings from AASLD and EASL ▶ <i>Program review and Post-test</i>

COURSE DIRECTORS

Paul Pockros, MD, FACP
Director, Liver Disease Center
Scripps Clinic
Director, SC Liver Research Consortium

Catherine Frenette, MD
Medical Director for Liver Transplantation
Scripps Center for Organ and Cell Transplantation

EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- ▶ Review the history, epidemiology, demographics, natural history, immunology, and pathophysiology that leads to increased incidence of viral hepatitis.
- ▶ Explore the factors that have led to a resurgence of Hepatitis A and the diagnostic and treatment guidelines for Delta Hepatitis and Hepatitis E.
- ▶ Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with viral hepatitis.
- ▶ Summarize the causes of chronic liver disease and hepatic encephalopathy and promising treatments.
- ▶ Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma (HCC).
- ▶ Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
- ▶ Review the current therapies for PBC and clinical approaches for PSC.
- ▶ Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management.
- ▶ Utilize current clinical cases to improve diagnostic and treatment skills.
- ▶ Improve the health of patients infected with hepatitis virus, liver cancer and other progressive liver diseases

REGISTRATION INFORMATION

	Live Seminar Early Registration	Live Seminar Regular Registration	Web-based Enduring Material
Physicians, Clinical Pharmacists and Administrators	\$135	\$150	\$95
Nurses, Nurse Practitioners and PA's	\$85	\$95	\$70
Medical Residents & Fellows	\$70	\$80	\$50

To Register & For More Information: <http://bit.ly/hepandCLD21>

Or call: SC Liver Research Consortium at (253) 432-4023

Early Registration ends Wednesday prior to program date.

Regular Registration begins Thursday prior to through program date.

Cancellation Policy: Requests for cancellation must be submitted to cmepd@louisville.edu at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

ACCREDITATION

Joint Provider Statement



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Physicians (MD/DO) - The University of Louisville School of Medicine designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1205. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners & Physician Assistants - AANP and AAPA accept Category I credit from **AMA PRA Category 1 Credit(s)™** organizations accredited by ACCME.

SPONSORS



The mission of the **University of Louisville** Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>



The **SC Liver Research Consortium** (SCLRC) is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to team research sponsors and SCLRC's over 90 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit www.scliver.com

DISCLOSURE

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.